Anti-CD33/Anti-CD3 Bispecific Antibody Armed Fresh Peripheral Blood Mononuclear Cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of fresh peripheral blood mononuclear cells (FPBMC) in which T-lymphocytes are coated with a bispecific antibody directed against the tumor-associated antigen (TAA) CD33 and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD33/anti-CD3 bispecific antibody armed FPBMCs target, bind to and selectively cross-link CD3-expressing T-cells and CD33-expressing tumor cells. This results in the activation of cytotoxic T-lymphocytes (CTLs) and selective cytotoxicity towards the CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.

**Synonyms:** - Anti-CD3 x Anti-CD33 Bispecific Antibody Armed Fresh Peripheral Blood Mononuclear Cells - Anti-CD33/Anti-CD3 Bispecific Antibody Armed FPBMC - Anti-CD33/CD3 Bispecific Antibody Armed Fresh Peripheral Blood Mononuclear Cells - CD33 FPBMC - CD33 x CD3 Bispecific Antibody Armed Fresh Peripheral Blood Mononuclear Cells